Continuous Glucose Monitoring in Intensive Care Unit

Critical Care Clinical Trial

Official title:

Continuous Glucose Monitoring in Intensive Care Unit

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05585801
• Other study ID #: CGM 001
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: December 2026

Study information

• Verified date: March 2024
• Source: Institute for Clinical and Experimental Medicine
• Contact: Barbora Hagerf, MD
• Phone: 00420608301443
• Email: barbora.voglova[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glucose control in ICU patients is challenging and exerts high burden on the nursing staff. Continuous glucose monitors (CGM) are now approved and widely available in the outpatient setting for patients with diabetes mellitus. However, only minimal evidence on CGM performance, reliability and benefit in achieving desired glucose control in the intensive care setting has been gathered so far.

The objective of this study is to assess whether the use of CGM helps to maintain blood glucose levels within the time in range recommended for patients in the intensive care.

In addition, accuracy of the sensor will be evaluated and compared to measurements of blood glucose by standardized biochemistry methods.

Description:

This will be a non-commercial, investigator-driven, active comparator-controlled, randomized, open-label and non-inferiority clinical study to be performed at the Institute for Clinical and Experimental Medicine in Prague. Patients that are being prepared for one of the surgical procedures mentioned below will be asked to participate:

1. pancreas surgery - total or partial pancreas resection

2. orthotopic liver transplantation

3. simultaneous pancreas and kidney transplantation

4. patients with diabetes mellitus undergoing major surgery

After obtaining the informed consent, they will be randomized into one of two treatment groups:

1. Study arm with continuous glucose monitor added to standard treatment, where the values obtained by CGM will aid in adjusting the insulin treatment.

2. Control arm with blinded continuous glucose monitor that will be treated according to the standard of care, where the CGM data will be collected in a blind fashion and evaluated after completion of the follow-up.

Each surgical group will be randomized and evaluated separately and independently.

Continuous glucose monitoring will be initiated after completing the surgical procedure in order to avoid interferences during the procedure.

Insulin therapy will be adjusted according to the standard in-house ICU protocol for insulin dose adjustment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female patients, of 18 to 80 years of age, undergoing one of the following surgical procedures and post-operative care at ICU:

1. pancreas surgery - total or partial pancreas resection

2. orthotopic liver transplantation

3. simultaneous pancreas and kidney transplantation

4. patients with diabetes mellitus undergoing major surgery

2. Patient must have signed the Patient Informed Consent Form.

Exclusion Criteria:

Any criteria that would disable surgical procedures involved

Related Conditions & MeSH terms

• Blood Glucose
• Critical Care

Intervention

Device:
• Dexcom G6 continuous glucose monitor
Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l. In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms.

Diagnostic Test:
• Blood glucose measurements according to standards of care
Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.

Locations

Country	Name	City	State
Czechia	Institute for Clinical and Experimental Medicine	Prague

Sponsors (1)

Lead Sponsor	Collaborator
Institute for Clinical and Experimental Medicine

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time in target range of 6-10 mmol/l		From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Mean blood glucose levels		From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Time spent in hyperglycaemia level 1 (glucose levels 10.1-13.9 mmol/l )	Amount of time (%) spent in hyperglycaemia level 1 (glucose levels 10.1-13.9 mmol/l )	From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Time spent in hyperglycaemia level 2 (glucose levels above 13.9 mmol/l )	Amount of time (%) spent in hyperglycaemia level 2 (glucose levels above 13.9 mmol/l )	From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Time spent in hypoglycaemia level 1 (glucose levels 3.0-3.8 mmol/l )	Amount of time (%) spent in hypoglycaemia level 1 (glucose levels 3.0-3.8 mmol/l )	From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Time spent in hypoglycaemia level 2 (glucose levels below 3 mmol/l )	Amount of time (%) spent in hypoglycaemia level 2 (glucose levels below 3 mmol/l )	From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Glycaemic variability assessed by standard deviation of blood glucose levels		From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Glycaemic variability assessed by coefficient of variation (%CV)		From the time of continuous glucose sensor insertion, which will be performed after admission to postoperative ICU, until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Daily dose of insulin	Daily dose of insulin and dosing speed throughout the day	From admission until the discharge from postoperative ICU, approx. 5-7 days
Secondary	Surgical complications	Surgical site infections, wound dehiscence, wound leakage	From admission to postoperative ICU until the discharge from hospital, approx. 10-15 days
Secondary	Infectious complications	Pneumonia, abdominal sepsis, urosepsis	From admission to postoperative ICU until the discharge from hospital, approx. 10-15 days
Secondary	Time until discharge from the inpatient care		From admission to postoperative ICU until the discharge from hospital, approx. 10-15 days